CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva

Shares of Catalyst Pharmaceuticals (CPRX) gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals (TEVA) regarding the Firdapse (amifampridine) patent litigation.The settlement agreement resolves the patent litigation brought by Catalyst and SERB on Teva for submitting an abbreviated new drug application (ANDA) to the FDA seeking marketing approval for a generic version of Firdapse 10 mg tablets before ap ...